TGF-β in cancer and bone: Implications for treatment of bone metastases

Patricia Juárez, Theresa A. Guise

Research output: Contribution to journalReview article

96 Scopus citations

Abstract

Bone metastases are common in patients with advanced breast, prostate and lung cancer. Tumor cells co-opt bone cells to drive a feed-forward cycle which disrupts normal bone remodeling to result in abnormal bone destruction or formation and tumor growth in bone. Transforming growth factor-beta (TGF-β) is a major bone-derived factor, which contributes to this vicious cycle of bone metastasis. TGF-β released from bone matrix during osteoclastic resorption stimulates tumor cells to produce osteolytic factors further increasing bone resorption adjacent to the tumor cells. TGF-β also regulates 1) key components of the metastatic cascade such as epithelial-mesenchymal transition, tumor cell invasion, angiogenesis and immunosuppression as well as 2) normal bone remodeling and coupling of bone resorption and formation. Preclinical models demonstrate that blockade of TGF-β signaling is effective to treat and prevent bone metastases as well as to increase bone mass.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalBone
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2011

Keywords

  • Bone metastasis
  • Breast cancer
  • Prostatic cancer
  • TGF-β
  • TGF-β inhibitors

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Fingerprint Dive into the research topics of 'TGF-β in cancer and bone: Implications for treatment of bone metastases'. Together they form a unique fingerprint.

  • Cite this